Baum, C., Shaffer, M. and Stillman, S. (2003), “Instrumental Variables and GMM: Estimation and Testing.” The Stata Journal, Vol. 3 No. 1, pp. 1-31.
Becker, S. and Ichino, A. (2002), “Estimation of Average Treatment Effects Based on Propensity Scores.” The Stata Journal, Vol. 2 No. 4, pp. 358-377.
Bradford, D. et al. (2006), “Effects of Direct-to-Consumer Advertising of Hydroxymethylglutaryl Coenzyme A Reductiase Inhibitors on Attainment of LDL-C Goals”, Clinical Therapeutics, Vol. 23 No. 12, pp. 2105-18.
Dezii, C.M. (2000), “Medication Noncompliance: What is the Problem?”, Managed Care, Vol. 9 No. 9, pp. 7-12.
Dor, A. (2004), “Optimal Price Rules, Administered Prices and Suboptimal Prevention: Evidence from a Medicare Program”, Journal of Regulatory Economics, Vol. 25 No. 1, pp. 81-104.
Dor, A. and Encinosa, W. (2004), “Does Cost-Sharing Affect Compliance? The Case of Prescription Drugs”, National Bureau of Economic Research Working Paper 10738, September, 2004. NBER: Cambridge, MA.
Dor, A. and Encinosa, W. (2010), “How Does Cost-Sharing Affect Drug Purchases? Insurance Regimes in the Private Market for Prescription Drugs. Journal of Economics and Management Strategy, 19:3 forthcoming. [OpenAIRE]
Fendrick, A.M., Smith, D.G., Chernew, M.E., et al. (2001), “A Benefit-Based Copay for Prescription Drugs: Patient Contribution Based on Total Benefits, Not Drug Acquisition Cost”, American Journal of Managed Care, Vol. 7 No. 9, pp. 861-867.
Frank, R.G. and Newhouse, J.P. (2008), “Should Drug Prices Be Negotiated Under Part D of Medicare? And If So, How?”, Health Affairs, Vol. 27 No. 1, pp. 33-42.
Fuhrmans, V. (2004), “A Radical Prescription”, Wall Street Journal, May, 10, 2004. pp.
Garber, Alan M. and McClellan, Mark B. (2007), “Satisfaction Guaranteed---“Payment by Results” for Biologic Agents”, New England Journal of Medicine, Vol. 357 No. 16, pp. 1575-1577.
Gaynor, Martin, Li, Jian and Vogt, William B. (2007), “Substitution, Spending Offsets, and Prescription Drug benefit Design”, Forum for Health Economics and Policy, Vol. 10 No. 2, pp. 1-31.
Gibson TB, Ozminkowski RJ, and Goetzel RZ. (2005), “The effects of prescription drug cost sharing: a review of the evidence”, American Journal of Managed Care, Vol. 11 No. 11, pp. 730-740.
Goldman, Dana P., Joyce, Geoffrey F. and Zheng, Yuhui (2007), “Prescription Drug Cost Sharing: Associations with Medication and Medical Utilization and Spending and Health”, Journal of the American Medical Association, Vol. 298 No. 1, pp. 61-69, E1- E18.